MEGHAN CHARLES: Open Payments
NPI 1629836457 · EXTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,107 in 101 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $760 · 2025 $2,107
Food & beverage: $1,984Education: $123
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 11 | $362 |
| Vanda Pharmaceuticals Inc. | 17 | $360 |
| ABBVIE INC. | 20 | $279 |
| Neurocrine BioSciences, Inc. | 8 | $181 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $179 |
| Otsuka America Pharmaceutical, Inc. | 11 | $168 |
| Teva Pharmaceuticals USA, Inc. | 5 | $162 |
| E.R. Squibb & Sons, L.L.C. | 5 | $117 |
| Alkermes, Inc. | 4 | $86 |
| Axsome Therapeutics, Inc. | 4 | $80 |
Products named: FANAPT, INVEGA SUSTENNA, VRAYLAR, INGREZZA, CAPLYTA, COBENFY, REXULTI, ARISTADA.
Industry payments across PA — which companies pay providers there.
